Catch up on the top radiology content of the past week.
|Articles|May 14, 1997
Mallinckrodt to distribute Myoview
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of
Advertisement
Mallinckrodt has added another agent to its line of nuclear medicine imaging products. The vendor has signed a five-year agreement with Medi-Physics to distribute Myoview, a technetium-based cardiac imaging agent that provides physicians a view of restricted blood supply to the heart muscle, according to the company.
Mallinckrodt of St. Louis and Medi-Physics of Arlington Heights, IL, will both provide the agent in the U.S. The agreement also includes a five-year extension.
In other Mallinckrodt news, the company has jointly announced with Molecular Biosystems that MBI's FS069 second-generation ultrasound contrast agent has been given the brand name Optison. Regulatory activity by the Food and Drug Administration on that agent has been temporarily halted following a U.S. District Court preliminary injunction on April 21 (SCAN 4/30/97).
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5